156 related articles for article (PubMed ID: 28562105)
1. Prasugrel hydrochloride for the treatment of sickle cell disease.
Conran N; Rees DC
Expert Opin Investig Drugs; 2017 Jul; 26(7):865-872. PubMed ID: 28562105
[TBL] [Abstract][Full Text] [Related]
2. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
3. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski JA; Zhou C; Winters KJ; Lachno DR; Howard J; Payne CD; Mant T; Jurcevic S; Frelinger AL
Platelets; 2015; 26(5):474-9. PubMed ID: 25140584
[TBL] [Abstract][Full Text] [Related]
4. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
[TBL] [Abstract][Full Text] [Related]
5. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
[TBL] [Abstract][Full Text] [Related]
6. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
Jakubowski JA; Zhou C; Jurcevic S; Winters KJ; Lachno DR; Frelinger AL; Gupta N; Howard J; Payne CD; Mant TG
Thromb Res; 2014 Feb; 133(2):190-5. PubMed ID: 24368019
[TBL] [Abstract][Full Text] [Related]
8. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
Jakubowski JA; Erlinge D; Alexopoulos D; Small DS; Winters KJ; Gurbel PA; Angiolillo DJ
Am J Cardiovasc Drugs; 2017 Apr; 17(2):109-121. PubMed ID: 27854064
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Wun T; Soulieres D; Frelinger AL; Krishnamurti L; Novelli EM; Kutlar A; Ataga KI; Knupp CL; McMahon LE; Strouse JJ; Zhou C; Heath LE; Nwachuku CE; Jakubowski JA; Riesmeyer JS; Winters KJ
J Hematol Oncol; 2013 Feb; 6():17. PubMed ID: 23414938
[TBL] [Abstract][Full Text] [Related]
10. Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
Torres L; Conran N
Expert Opin Pharmacother; 2019 Feb; 20(2):173-186. PubMed ID: 30499731
[TBL] [Abstract][Full Text] [Related]
11. Platelet activation and inhibition in sickle cell disease (pains) study.
Frelinger AL; Jakubowski JA; Brooks JK; Carmichael SL; Berny-Lang MA; Barnard MR; Heeney MM; Michelson AD
Platelets; 2014; 25(1):27-35. PubMed ID: 23469943
[TBL] [Abstract][Full Text] [Related]
12. Oral Antiplatelet Therapy in Coronary Disease.
Falcão Gonçalves P; Menezes Falcão L
Am J Ther; 2017; 24(6):e744-e750. PubMed ID: 26752652
[TBL] [Abstract][Full Text] [Related]
13. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Badawy SM
N Engl J Med; 2016 Jul; 375(2):185. PubMed ID: 27410931
[No Abstract] [Full Text] [Related]
15. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Rees DC
N Engl J Med; 2016 Jul; 375(2):185-6. PubMed ID: 27410930
[No Abstract] [Full Text] [Related]
16. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Jakubowski JA; Zhou C; Small DS; Winters KJ; Lachno DR; Frelinger AL; Howard J; Mant TG; Jurcevic S; Payne CD
Br J Clin Pharmacol; 2013 Jun; 75(6):1433-44. PubMed ID: 23171128
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Guimarães PO; Tricoci P
Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis.
Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Res; 2015 Dec; 136(6):1224-30. PubMed ID: 26388120
[TBL] [Abstract][Full Text] [Related]
19. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
20. Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial.
Schoergenhofer C; Schwameis M; Hobl EL; Ay C; Key NS; Derhaschnig U; Jilma B; Spiel AO
Clin Sci (Lond); 2016 Mar; 130(6):433-40. PubMed ID: 26554025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
